A Phase 3, Open-Label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

About this Study

This study will evaluate the long-term effects of an experimental drug in Cystic Fibrosis patients who completed a previous Vertex study. 

Sponsor Protocol ID:VX17-659-105
IRB Number:2018-0129
Closed for Enrollment
Interventional
Phase 3
June 27, 2019
Eligibility Criteria
12 years old
100 years old
Both Male and Female
No
Yes
Yes

Inclusion Criteria1. Subject (or his or her legally appointed and authorized representative) will sign and date an informed consent form (ICF), and, when appropriate, an assent form. 

2. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. 

3. Did not withdraw consent from a parent study. 

4. Meets at least 1 of the following criteria: 
  •  Completed study drug treatment in a parent study. 
  •  Had study drug interruption(s) in a parent study, but completed study visits up to the last scheduled visit of the Treatment Period of a parent study. 

5. Willing to remain on a stable CF treatment regimen (as defined in Section 9.5) through completion of study participation. 

Exclusion Criteria1. History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. 

2. Pregnant and nursing females. Females of childbearing potential must have a negative pregnancy test at the Day 1 Visit before receiving the first dose of study drug. 

3. History of drug intolerance in a parent study that would pose an additional risk to the subject in the opinion of the investigator. (e.g., subjects with a history of allergy or hypersensitivity to the study drug.) 

4. Current participation in an investigational drug trial (other than a parent study). Participation in a noninterventional study (including observational studies, registry studies, and studies requiring blood collections without administration of study drug) and screening for another Vertex study is permitted.